Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis.

ABSTRACT:

Objectives

Based on the acknowledged organ-specific immune microenvironment, little is known regarding the efficacy of immunotherapy in patients with lung cancer according to metastatic sites. This meta-analysis aimed to explore the efficacy of immune checkpoint inhibitors (ICIs) vs chemotherapy in patients with lung cancer with liver metastases (LM) or brain metastases (BM).

Design

Meta-analysis and systematic review.

Data sources

We systematically searched in electronic databases (PubMed, EMBASE, Cochrane Library and Web of Science), up to 31 January 2022. We also reviewed the abstracts from major international conferences. Eligibility criteria were randomised controlled phase II or III trials reporting the overall survival (OS) or progression-free survival (PFS) of

SUBMITTER: Yu S 

PROVIDER: S-EPMC10030562 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature